Abstract：[Abstract]Objective To investigate the clinical effect of Paroxetine in the treatment of Parkinson′s disease with depression.Mehods Sixty patients with Parkinson′s disease accompanied by depression who were admitted to our hospital from January 2018 to January 2019 were selected as the research subjects，they were divided into observation group and control group according to the random number allocation principle，with 30 cases in each group.The control group was given routine treatment，and the observation group was treated with Paroxetine Tablets on the basis of the control group for 8 weeks.The unified Parkinson′s disease rating scale（UPDRS）and Hamilton depression scale（HAMD）scores were compared before and after treatment.Results The UPDRS score of the observation group was lower than that of the control group 8 weeks after treatment，the difference was statistically significant（P＜0.05）.The HAMD score of the observation group was lower than that of the control group at 4 and 8 weeks after treatment，the differences were statistically significant（P＜0.05）.Conclusion The application of Paroxetine in the treatment of Parkinson′s disease with depression can alleviate the symptoms and depression of patients，which is worthy of clinical application.
Santos García D，de Deus Fonticoba T，Suárez Castro E，et al.Non-motor symptoms burden，mood，and gait problems are the most significant factors contributing to a poor quality of life in non-demented Parkinson′s disease patients：results from the COPPADIS study cohort[J].Parkinsonism Relat Disord，2019，66：151-157.
Lin CH，Park C，McIntyre RS.Early improvement in HAMD-17 and HAMD-7 scores predict response and remission in depressed patients treated with fluoxetine or electroconvulsive therapy[J].J Affect Disord，2019，253：154-161.
[10]
Huang L，Ren Y，Zeng Z，et al.Comparative study of striatum GABA concentrations and magnetic resonance spectroscopic imaging in Parkinson′s disease monkeys[J].BMC Neurosci，2019，20（1）：42.
[12]
Barbosa ENBE，Charchat-Fichman H.Systematic review of neuropsychological instruments used in subthalamic nucleus deep brain stimulation in Parkinson′s disease patients[J].Dement Neuropsychol，2019，13（2）：162-171.
Aboulghasemi N，Hadipour Jahromy M，Ghasemi A.Antidyskinetic efficacy of 5-HT3 receptor antagonist in the hemi-parkinsonian rat model[J].IBRO Rep，2018，6：40-44.
Carboni L，McCarthy DJ，Delafont B，et al.Biomarkers for response in major depression：comparing paroxetine and venlafaxine from two randomised placebo-controlled clinical studies[J].Transl Psychiatry，2019，9（1）：182.
[18]
Purgato M，Papola D，Gastaldon C，et al.Paroxetine versus other anti-depressive agents for depression[J].Cochrane Database Syst Rev，2014，（4）：CD006531.
京公网安备 11010502046607号